MedElevator Войти в исследования
← Поиск публикаций

DOI 10.15252/emmm.201707860

Медицинская библиотека · EMBO molecular medicine · 2017

SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis.

Athwal Varinder S, Pritchett James, Llewellyn Jessica, Martin Katherine, Camacho Elizabeth, Raza Sayyid Ma, Phythian-Adams Alexander, Birchall Lindsay J, Mullan Aoibheann F, Su Kim, Pearmain Laurence, Dolman Grace, Zaitoun Abed M, Friedman Scott L, MacDonald Andrew, Irving William L, Guha Indra N, Hanley Neil A, Piper Hanley Karen

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Fibrosis and organ failure is a common endpoint for many chronic liver diseases. Much is known about the upstream inflammatory mechanisms provoking fibrosis and downstream potential for tissue remodeling. However, less is known about the transcriptional regulation in vivo governing fibrotic matrix deposition by liver myofibroblasts. This gap in understanding has hampered molecular predictions of disease severity and clinical progression and restricted targets for antifibrotic drug development. In this study, we show the prevalence of SOX9 in biopsies from patients with chronic liver disease correlated with fibrosis severity and accurately predicted disease progression toward cirrhosis. Inactivation of Sox9 in mice protected against both parenchymal and biliary fibrosis, and improved liver function and ameliorated chronic inflammation. SOX9 was downstream of mechanosignaling factor, YAP1. These data demonstrate a role for SOX9 in liver fibrosis and open the way for the transcription factor and its dependent pathways as new diagnostic, prognostic, and therapeutic targets in patients with liver fibrosis.

Для цитирования: Athwal Varinder S, Pritchett James, Llewellyn Jessica, Martin Katherine, Camacho Elizabeth, Raza Sayyid Ma, Phythian-Adams Alexander, Birchall Lindsay J, Mullan Aoibheann F, Su Kim, Pearmain Laurence, Dolman Grace, Zaitoun Abed M, Friedman Scott L, MacDonald Andrew, Irving William L, Guha Indra N, Hanley Neil A, Piper Hanley Karen. SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis.. EMBO molecular medicine. 2017. DOI: 10.15252/emmm.201707860.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.